Search
Protalix Biotherapeutics Inc
PLXAdd to Watchlist
2.320USD
+0.015+0.65%
Close 07/02, 13:00（ET）Quotes delayed by 15 min
186.93MMarket Cap
12.01P/E TTM
View Detailed Chart
TradingKey 图表Intraday
1m
30m
1h
D
W
M
D
Today
+0.65%
5 Days
+0.87%
1 Month
+15.42%
6 Months
+33.33%
Year to Date
+28.89%
1 Year
+50.65%
Key Figures
2.300Open
2.355High
472.79KVolume
12.01P/E TTM
45.89P/E Dynamic
--Dividend TTM
0.59%Turnover Ratio
2.300Prev. Close
2.270Low
561.43KTurnover
63.75P/E Static
2.78P/B
0.00%Div Yield TTM
-8.48%ROA
3.19052wk High
0.89Volume Ratio
2.93MNet Profit
80.57MShares
0.1932EPS TTM
-0.02Beta
-14.44%ROE
1.32052wk Low
3.70%Amplitude
87.77%Gross Margin
186.93MMarket Cap
4.26Reward/Risk
3.38%Risk Rate
TradingKey Stock Score of Protalix Biotherapeutics Inc
Currency: USD Updated: 2026-07-02Key Insights
Protalix Biotherapeutics Inc's fundamentals are relatively very healthy, and its growth potential is high.Its valuation is considered fairly valued, ranking 76 out of 157 in the Pharmaceuticals industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 11.00.In the medium term, the stock price is expected to remain stable.The company has been performing strongly in the stock market over the past month, which is supported by its strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Protalix Biotherapeutics Inc's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Neutral
Protalix Biotherapeutics Inc Highlights
StrengthsRisks
Protalix BioTherapeutics, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of recombinant therapeutic proteins expressed through its proprietary plant cell-based expression system, ProCellEx. In addition, the Company is developing PEGylated uricase, or PRX-115, for the treatment of uncontrolled gout, Long Acting (LA) DNase I, or PRX-119, for the treatment of NETs-related diseases, and other technologies and preclinical assets. Its ProCellEx platform is being used to manufacture both of its approved and marketed products as well as PRX-115 and PRX-119. PRX-115, a plant cell-expressed recombinant PEGylated Uricase (urate oxidase) - a chemically modified enzyme to treat uncontrolled gout. PRX-119 is a plant cell-expressed PEGylated recombinant human DNase I product candidate. Its product includes Elelyso and Elfabrio. Elelyso is an enzyme replacement therapy (ERT) for the treatment of patients with Gaucher disease.
Growing
The company is in a growing phase, with the latest annual income totaling USD 52.74M.
Turnaround to Loss
The company's performance has turned to a loss, with the latest annual loss of USD .
Fairly Valued
The company’s latest PE is 12.01, at a medium 3-year percentile range.
Institutional Buying
The latest institutional holdings are 19.91M shares, increasing 9.74% quarter-over-quarter.
Held by Bill Nygren | OAKMX
Star Investor Bill Nygren | OAKMX holds 38.91K shares of this stock.
Analyst Rating
Based on
1
analysts
Buy
Current Rating
11.000
Target Price
+378.26%
Upside Space
Protalix Biotherapeutics Inc News
More news coming soon, stay tuned...
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
Protalix Biotherapeutics Inc Info
Protalix BioTherapeutics, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of recombinant therapeutic proteins expressed through its proprietary plant cell-based expression system, ProCellEx. In addition, the Company is developing PEGylated uricase, or PRX-115, for the treatment of uncontrolled gout, Long Acting (LA) DNase I, or PRX-119, for the treatment of NETs-related diseases, and other technologies and preclinical assets. Its ProCellEx platform is being used to manufacture both of its approved and marketed products as well as PRX-115 and PRX-119. PRX-115, a plant cell-expressed recombinant PEGylated Uricase (urate oxidase) - a chemically modified enzyme to treat uncontrolled gout. PRX-119 is a plant cell-expressed PEGylated recombinant human DNase I product candidate. Its product includes Elelyso and Elfabrio. Elelyso is an enzyme replacement therapy (ERT) for the treatment of patients with Gaucher disease.
Ticker SymbolPLX
CompanyProtalix Biotherapeutics Inc
CEOBashan (Dror)
Websitehttps://protalix.com/
Related Instruments
+1.62%
+3.50%
+6.14%
+3.96%
+3.31%
+3.72%
+3.55%
+3.40%
+4.21%
+1.80%
+6.03%
+4.11%
+4.62%
+3.68%
+2.35%
0.00%
+4.73%
+3.32%
+0.41%
+4.98%Popular Instruments
52852.900
+10.400 (+0.02%)
29669.900
+358.500 (+1.22%)
7507.800
+36.300 (+0.49%)
14963.000
+160.000 (+1.08%)
69676.000
+1528.000 (+2.24%)
6412.400
+59.600 (+0.94%)
68.683
+0.339 (+0.50%)
308.630
+14.250 (+4.84%)
194.830
-2.750 (-1.39%)
4174.610
+52.700 (+1.28%)
FAQs
What is the current price of Protalix Biotherapeutics Inc (PLX)?
The current price of Protalix Biotherapeutics Inc (PLX) is 2.32.
What is the symbol of Protalix Biotherapeutics Inc?
The ticker symbol of Protalix Biotherapeutics Inc is PLX.
What is the 52-week high of Protalix Biotherapeutics Inc?
The 52-week high of Protalix Biotherapeutics Inc is 3.19.
What is the 52-week low of Protalix Biotherapeutics Inc?
The 52-week low of Protalix Biotherapeutics Inc is 1.32.
What is the market capitalization of Protalix Biotherapeutics Inc?
The market capitalization of Protalix Biotherapeutics Inc is 186.93M.
Is Protalix Biotherapeutics Inc (PLX) currently rated as Buy, Hold, or Sell?
According to analysts, Protalix Biotherapeutics Inc (PLX) has an overall rating of Buy, with a price target of 11.00.
What is the Earnings Per Share (EPS TTM) of Protalix Biotherapeutics Inc (PLX)?
The Earnings Per Share (EPS TTM) of Protalix Biotherapeutics Inc (PLX) is -0.08.